Daily Stock List
BioVie, Inc. (BIVI)
Wealth Insider Alert reported earlier on BioVie, Inc. (BIVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
A development-stage company, BioVie, Inc. focuses on the discovery, development, and commercialization of innovative drug therapies for liver disease. At present, BioVie is concentrating on commercializing BIV201, which is a novel approach to the treatment of ascites because of chronic liver cirrhosis. BioVie is based in Beverly, Massachusetts and the Company’s shares trade on the OTCQB Market.
BioVie submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for BIV201 late last year. The Company is waiting on clearance to commence a clinical trial program. BioVie said that this new drug candidate could potentially enter a mid-stage (Phase 1b) US clinical trial in the first half of this calendar year.
It said that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a considerable unmet medical need.
The FDA has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at over $4 billion each year.
In February, BioVie announced that it submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by the Company in January 2017.
Mr. Jonathan Adams, BioVie Chief Executive Officer, said, "The FDA requested more information about the ambulatory pumps to be used in our clinical study. We have provided this information and conducted 3 bench studies, all with supportive results. Additionally, we incorporated the Agency's suggestions to improve the quality of our planned clinical study."
Yesterday, BioVie announced the appointment of Ms. Julie G. Anderson as an independent member of BioVie’s Board of Directors. Ms. Anderson has much experience in the pharma/biotech industry.
She most recently served Catheter Connections, Inc. as its Vice President of Marketing until the company was sold in February 2017. Previously she was Senior Director of Marketing for Durata Therapeutics, Inc.
BioVie, Inc. (BIVI), closed Thursday's trading session at $0.29, up 11.54%, on 41,612 volume with 13 trades. The average volume for the last 60 days is 6,028 and the stock's 52-week low/high is $0.06/$0.45.
Cell Source, Inc. (CLCS)
We are highlighting Cell Source, Inc. (CLCS) today, here at the QualityStocks Daily Newsletter.
Cell Source, Inc. is a biotechnology company listed on the OTC Markets Group’s OTCQB. The Company focuses on developing cell therapy treatments based on immunotherapy and regenerative medicine. Its chief product is the Veto-Cell immune system management technology. Cell Source is working to transform transplantation, cancer treatment and the reversal of vital organ disease, employing its cutting-edge immune tolerance and organ regeneration technologies. Cell Source is headquartered in New York, New York.
Cell Source’s Veto-Cell immune system management technology is an immune tolerance biotechnology. It enables the selective blocking of immune responses. The Company’s Veto-Cell technology is utilized in varied applications. These include bone marrow transplantation, veto-cell in transplantation, anti-cancer, and non-malignant diseases.
Along with its Veto Cells technology, Cell Source has its Megadose Drug Combination technology. The method of action includes stem cells overcoming rejection by outnumbering immune rejecting cells, and drugs reduce the need for immune suppression.
The Company’s patented Veto-Cell technology addresses one of the most fundamental challenges in human immunology. This challenge is: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats.
The Company’s Veto cells disable the attack of the immune system on the bone marrow transplantation (BMT) only, without other side effects. The Veto cells act as “decoys” that attract, then kill, the T-cell clones directed at the transplant. The Veto cells
continue “on guard” in the body for lengthy periods of time to further limit rejection. Therefore, the transplantation is accepted by the body without compromising the rest of the immune system.
Regarding its Intellectual Property (IP), Cell Source has a considerable IP Portfolio, exclusively licensed to Cell Source from the Weizmann Institute of Science through Yeda Research and Development Company Ltd. covering Dr. Yair Reisner’s technologies. Dr. Yair Reisner is former Chairman of the Department of Immunology of Israel’s Weizmann Institute of Science. He pioneered “mismatched” BMT (partial versus full donor/recipient match) with his patented “Megadose” cell therapy treatment.
The primary goal in developing Veto Cells is to have a meaningful and potentially comprehensive impact on the field of bone marrow and major organ transplantation. In addition, Veto Cells can be combined with other cell therapy treatments to improve their effectiveness. In preclinical studies, Veto Cells have been shown to increase persistence and efficacy of genetically modified cells.
Cell Source, Inc. (CLCS), closed Thursday's trading session at $0.50, up 14.94%, on 500 volume with 1 trade. The average volume for the last 60 days is 9,857 and the stock's 52-week low/high is $0.35/$1.50.
Grow Solutions Holdings, Inc. (GRSO)
Profitable Trader Authority, Stockgoodies, PennyStockScholar, OTCtipReporter, StockRockandRoll, ResearchOTC, Journal Transcript, Elite Stock Alerts, and PennyStockLocks reported on Grow Solutions Holdings, Inc. (GRSO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Grow Solutions Holdings, Inc. provides complete support services in the broad area of high-yield indoor agriculture. The Company specializes in, but is not limited to the legal and regulated growing and processing of cannabis. Its corporate mission is to be recognized as the world’s leading authority in the indoor high-yield agriculture industry. In essence, Grow Solutions concentrates on the development/distribution of high-demand products and services for cultivation, processing, and consumption of cannabis.
Grow Solutions’ diversified platform of operations and services for the industry consists of its Growth Technologies division (products needed to grow cannabis in and outside), its Consumer Technologies division (products to process, store and consume cannabis), and its Digital Properties division (online properties, including a state of the art employment platform).
In May of 2015, the Company acquired Boulder, Colorado-based One Love Garden Supply. One Love is a full-service garden and grow store, which Grow Solutions expanded to more than 7,000 square feet of space.
Furthermore, in September 2015, Grow Solutions acquired HyGrow to expand its gardening supplies and agricultural products business. The acquisition enabled it to expand into Denver and Pueblo, Colorado.
In March of 2016, Grow Solutions developed and launched FutureTech Products (Pompano, Florida-based). FutureTech develops products for the consumer market to sell in smoke shops, head shops, as well as dispensaries. In addition, in April 2016, Grow Solutions acquired Mile High Hydro. This is a full service online grow store. It offers a wide-ranging line of gardening supply and agricultural products to growers throughout the country.
In January 2017, Grow Solutions Holdings announced that it acquired West Coast Organic and Hydroponic Supply (WCO) in Boring, Oregon. West Coast Organic & Hydroponic has attained more than $2 Million in revenues for 2016 and is profitable. Grow Solutions projects that it will more than double these revenues to greater than $4 Million this year.
Last month, Grow Solutions Holdings announced that it acquired Keys Organic and Hydroponic Supply (Keys) in the state of Florida. The acquisition of Keys expands on Grow Solutions’ existing operations in the southeast by way of its Future Tech division through providing a strategic location for the entry of the Company's One Love Garden Supply subsidiary into east coast markets.
The Keys location will handle all Grow Solutions shipping needs to supply the Company’s customers throughout the east coast. Moreover, the location will support its online sales efforts.
Grow Solutions Holdings, Inc. (GRSO), closed Thursday's trading session at $0.14, up 10.24%, on 251,647 volume with 61 trades. The average volume for the last 60 days is 165,754 and the stock's 52-week low/high is $0.0774/$1.92.
AfterMaster, Inc. (AFTM)
Wall Street Mover, Equities.com, and TopPennyStockMovers reported earlier on AfterMaster, Inc. (AFTM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed, AfterMaster, Inc. is an industry leading audio technology company. AfterMaster is a cutting-edge audio technology originally developed for the mastering, re-mastering, and processing of audio through AfterMaster HD Audio Labs, Inc. The Company’s executive team includes music and audio technology leaders Justin Timberlake, Rodney "Darkchild" Jerkins, Pete Doell, Andrew Wuepper, Shelly Yakus, and Larry Ryckman. AfterMaster is based in Hollywood, California.
AfterMaster delivers a consummate clarity, depth, and fullness to audio recordings. It does so while delivering a substantial increase in volume without increased distortion or loss of dynamic range. The technology has been used by many top musicians looking to create a fuller and richer sound quality than otherwise available in digital audio.
AfterMaster’s ProMaster HD will be available on Adobe® Audition® CC. This is a professional audio workstation for mixing, finishing, and editing. ProMaster HD is the Company’s online audio mastering service. The integration of ProMaster HD enables Adobe Audition CC users to immediately master their original work directly within Adobe Creative Cloud®.
ProMaster HD instils the clearest, deepest sound quality into any recording. This raises that audio to a studio remastered sound experience.
AfterMaster announced a new partnership in 2016 with independent digital music distribution and publishing administration service, TuneCore. With the agreement, AfterMaster will serve as TuneCore's new professional mastering service, enabling and empowering users with direct access to award-winning senior mastering engineers in AfterMaster's state-of-the-art facilities.
AfterMaster announced in October 2016 the start of production on its new AfterMaster Pro. This is the world's first personal re-mastering device. The AfterMaster Pro masters and re-masters inconsistent sound in real-time. AfterMaster Pro is easily installed via HDMI cables between any TV and the A/V source (cable or satellite box, and more).
In addition, the portable device is equipped with a rechargeable battery and 1/8" audio ports. As a result, it can be used on-the-go to considerably improve the audio of smartphones, tablets, computers, as well as any audio-enabled device. AfterMaster Pro is manufactured in the U.S.A.
This past January, AfterMaster introduced a broad assortment of flagship products and services on the floor at CES 2017. The Company unveiled its latest innovations to show-goers, including the first personal audio re-mastering device AfterMaster Pro™, along with its online music mastering service, ProMaster and technology through software or DSP chip, BelaSigna 300.
AfterMaster, Inc. (AFTM), closed Thursday's trading session at $0.34, up 7.94%, on 1,691,313 volume with 194 trades. The average volume for the last 60 days is 9,477,209 and the stock's 52-week low/high is $0.0055/$0.142.
SNAP Interactive, Inc. (STVI)
Marketbeat, Greenbackers, TopPennyStockMovers, SmarTrend Newsletters, FeedBlitz, SmallCapVoice, PennyTrader Publisher, Global Equity Report, BullRally, CoolPennyStocks, HotOTC, Penny Invest, Stock Rich, StockEgg, OTC Picks, and Market Wrap Daily reported earlier on SNAP Interactive, Inc. (STVI), and we report on the Company today, here at the QualityStocks Daily Newsletter.
SNAP Interactive, Inc. develops, owns and operates dating applications for social networking websites and mobile platforms. The Company provides online dating applications under the FirstMet and The Grade brands in the U.S. The SNAP product portfolio also includes Paltalk and Camfrog that together host one of the world's largest collections of video-based communities.
SNAP Interactive is headquartered in New York, New York. The Company lists on the OTC Markets Group’s OTCQB.
SNAP Interactive's flagship brand is FirstMet (formerly AYI.com). SNAP rebranded AYI as FirstMet to reflect the Company’s vision for making it easier for single adults to meet new people in a friendly, low-pressure environment. FirstMet is a prominent interactive dating brand serving users 35 and older.
FirstMet is a multi-platform online dating site with a large user database. FirstMet‘s objective is to improve the online dating experience of meeting new people through integrating a user’s friends and interests to empower more meaningful connections. The FirstMet brand is fully integrated across Facebook, iPhone, Android, and the Worldwide Web. FirstMet is one of the first dating apps to integrate with Facebook.
Additionally, SNAP’s “The Grade” is a mobile dating application catering to high-quality singles. The Grade holds users accountable for their behavior through employing a proprietary algorithm.
This algorithm assigns letter grades to users ranging from "A+" to "F" based on profile quality, responsiveness, as well as peer-reviews generated from the opinions received from other users. Users with a grade of "D" or "F" receive a warning and also instructions on how to improve their grade. Users who maintain an "F" grade are expelled.
SNAP Interactive announced the closing of its merger with AVM Software, Inc. (d/b/a Paltalk), effective October 7, 2016. The mission of the combined company is to become the foremost platform in connecting a worldwide audience of users around interest categories and dating through taking advantage of live video and chat as the core method of communication.
SNAP also has its “Tinychat.” This is an online video chat community. Tinychat is available on PC, Mac, iOS, Android and tablet.
SNAP Interactive, Inc. (STVI), closed Thursday's trading session at $4.00, down 0.50%, on 9,976 volume with 22 trades. The average volume for the last 60 days is 3,474 and the stock's 52-week low/high is $1.05/$20.50.
LKA Gold, Inc. (LKAI)
BestDamnPennyStocks, DSR News, PHUB NEWS, TheNextBigTrade, TopPennyStockMovers, Penny Stocks VIP, Penny Pick Insider, Daily Stock Motion, Gryphon Digest, PennyStocks24, 007 Stock Chat, PennyStockSpy, OtcShortReport, and Information Solutions Group reported earlier on LKA Gold, Inc. (LKAI), and we report on the Company today, here at the QualityStocks Daily Newsletter.
LKA Gold, Inc.’s focus is on acquiring and developing properties in politically stable jurisdictions that can yield high profit margins even during volatile economic conditions. The Company’s Golden Wonder mine has a recent production history of 141,510 ounces of gold at an average ore grade of 11.63 ounces (362 grams) gold per ton and an average production cost of less than $150 per ounce. Golden Wonder is a very high-grade telluride (epithermal) gold deposit. LKA Gold is based in Gig Harbor, Washington.
Golden Wonder is located near Lake City, Colorado. The average grade of Golden Wonder ore (from 1998, through the second quarter of 2006) was 16.01 ozs. (454 grams) gold per ton. LKA’s belief is that additional such ore chutes may be on its mining claims.
Since restarting exploratory operations in Q1 2009, LKA Gold has shipped 27 bulk ore samples containing over 4,000 ounces of gold with a net value, after processing, of more than $4.2 million. LKA is continuing to evaluate financing options to expand/accelerate this program. A commercially viable ore reserve has yet to be established.
In July of 2015, LKA Gold announced that it executed an "Exploration Agreement & Option" with Kinross Gold USA Inc. for expanding its Golden Wonder Mine exploration beyond LKA's active workings. This Agreement, among its other provisions, grants Kinross Gold USA a five-year exclusive right to explore, and if successful, develop any mineral resource(s) containing 50,000 or more ounces of gold on LKA Gold's properties above and next to the Golden Wonder Mine.
Kinross Gold USA conducted a detailed evaluation of surface geology surrounding LKA's Golden Wonder mine. A report detailing Kinross' findings, earlier provided to LKA, indicates a number of prospective targets possessing similar characteristics to those found on surface above the earlier mined high-grade ore shoot.
This past December, LKA Gold announced that a Kinross Gold USA sponsored and directed surface drilling program is taking place at the first of four permitted sites situated on LKA mining claims very near the Company's Golden Wonder mine.
The drilling program began in late November 2016. The design of this program is to test four of six areas, earlier identified by Kinross Gold geologists, possessing geochemistry like that of the initial bonanza-grade discovery at LKA's Golden Wonder mine.
LKA Gold, Inc. (LKAI), closed Thursday's trading session at $0.45, up 12.50%, on 5,350 volume with 4 trades. The average volume for the last 60 days is 9,597 and the stock's 52-week low/high is $0.20/$0.68.
India Globalization Capital, Inc. (IGC)
The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.4132, up 21.53%, on 407,413 volume with 676 trades. The stock’s average daily volume over the past 60 days is 171,536, and its 52-week low/high is $0.19/$0.6701.
India Globalization Capital, Inc. was recently featured in an article detailing the company’s strategic move to the cannabis industry and future plans for the company. To view the full article, visit: http://m.benzinga.com/article/9165369
India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer
India Globalization Capital, Inc. Company Blog
India Globalization Capital, Inc. News:
NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Benzinga Article
IGC Announces Third Quarter Financial Results
India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant to its CFO
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.85, up 1.32%, on 15,055 volume with 35 trades. The stock’s average daily volume over the past 60 days is 12,266, and its 52-week low/high is $0.91/$5.84.
eXp World Holdings Inc. the holding company for eXp Realty LLC, The Agent-Owned Cloud Brokerage®, today announced that eXp Realty has grown its family of agents and brokers to more than 3,000 across all markets in the United States and Canada. The Company ended 2016 with 2,401 agents on its platform, and reached 3,000 agents on March 15, 2017, representing 25% growth year-to-date and growth of over 200% since March 15, 2016.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp Realty Reaches 3,000 Agent Milestone
eXp World Holdings to Present at Annual ROTH Conference
Super Bowl Quarterback Vince Ferragamo Joins eXp Realty
InMed Pharmaceuticals, Inc. (IMLFF)
The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.273, off by 3.07%, on 442,171 volume with 196 trades. The stock’s average daily volume over the past 60 days is 883,624, and its 52-week low/high is $0.05/$0.4261.
InMed Pharmaceuticals Inc.; NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF), an NNW client that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. To view the full publication visit: https://www.networknewswire.com/biotech-innovations-drive-cannabinoid-based-pharmaceutical-market-growth/
InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”
After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.
Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.
Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer
InMed Pharmaceuticals, Inc. Company Blog
InMed Pharmaceuticals, Inc. News:
NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use
InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.06, off by 6.25%, on 1,791,313 volume with 194 trades. The stock’s average daily volume over the past 60 days is 9,477,209, and its 52-week low/high is $0.0055/$0.142.
Singlepoint, Inc.; CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing SinglePoint's strategy to build a portfolio of cannabis-focused businesses by acquiring and incubating accretive small- to mid-sized companies that are involved in ancillary (e.g. non-drug-touching) areas of the market.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
SinglePoint Executes on Cannabis Acquisition Strategy -- CFN Media
Greg Lambrecht, CEO of SinglePoint Inc., Discusses Recent SING News and Industry Trends in A New Audio Interview withSmallCapVoice.com
Singlepoint Takes a Low Risk Approach to the Cannabis Industry -- CFN Media
Stealth Technologies Inc. (STTH)
The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.04, up 32.89%, on 34,200 volume with 2 trades. The stock’s average daily volume over the past 60 days is 38,350, and its 52-week low/high is $0.015/$0.05.
Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.
The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.
StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.
The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.
Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.
Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer
Stealth Technologies Inc. Company Blog
Stealth Technologies Inc. News:
Stealth Technologies Announces 5 New Products
Stealth Technologies Highlights Opportunities from Attendance at Leading Real Estate, Home Staging Conference
NetworkNewsWire Releases Exclusive Audio Interview with Stealth Technologies, Inc. (STTH)
ProBility Media Corp. (PBYA)
The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.5499, up 19.14%, on 5,442 volume with 2 trades. The stock’s average daily volume over the past 60 days is 1,041, and its 52-week low/high is $0.1205/$1.50.
ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.
Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.
Companies currently under the ProBility Media conglomerate include:
- Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
- Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
- 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
- National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.
ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.
The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer
ProBility Media Corp. Company Blog
ProBility Media Corp. News:
ProBility Media Corp. and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
ProBility Media Corp. Announces Philanthropic Initiative
Panther Biotechnology Inc. Announces Name Change to ProBility Media Corp.
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- ChineseInvestors.com, Inc. (CIIX) SeeThruEquity Issues Update on ChineseInvestors.com, Increasing Price Target to $3.75
- Dominovas Energy Corp. (DNRG) Enters Formal Negotiations to Open in India and Indonesia
- eXp World Holdings, Inc. (EXPI) eXp Realty Reaches 3,000 Agent Milestone
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) NetworkNewsBreaks – IGC CEO Featured in Benzinga Article
- InMed Pharmaceuticals Inc. (IMLFF) NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry
- ProBility Media Corp. (PBYA) and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
- Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
- Singlepoint, Inc. (SING) Executes on Cannabis Acquisition Strategy -- CFN Media
- Stealth Technologies, Inc. (STTH) Announces 5 New Products
- TapImmune, Inc. (NASDAQ: TPIV) Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer